Edoxaban: Completed Phase III enrollment

Daiichi completed enrollment of 21,107 AF patients in the double-blind, double-dummy, international Phase III ENGAGE AF-TIMI 48 trial comparing 30 or 60 mg once-daily edoxaban vs. warfarin. Edoxaban i...